Volgens een studie van Matthew Sorenson, Leonard Jason en een aantal anderen 

is de hoeveelheid brain-derived neurotrophic factor (BNDF, zenuw-celstimulerende factor)

die gemiddeld genomen door de witte bloedcellen van ME/CVS-patiënten geproduceerd wordt

slechts een kwart van de hoeveelheid die door de gezonde proefpersonen aangemaakt wordt.

Vergelijkbare (lage) concentraties BDNF werden ook bij MS-patiënten aangetroffen.

BDNF bevordert het overleven en de groei van verscheidene neuronen (zenuwcellen) en

draagt bij aan de vorming van nieuwe synapsen: verbindingen tussen neuronen (neuroplasticiteit).

Brain derived neurotrophic factor is decreased

in chronic fatigue syndrome and multiple sclerosis.

J Neurol Neurophysiol. 2014 Apr 30;S12: S2-013. doi:10.4172/2155-9562.S12-013.

Sorenson M, Jason L, Peterson J, Herrington J, Mathews H.

This article was originally published in a special issue, entitled:

"Neurodegenerative Diseases: Symptoms and Therapeutics",

Edited by Dr. Jin J Luo, Temple University School of Medicine, USA

ISSN: 2155-9562

Abstract

Objective:

This study examined

the levels of a major regulator of neuronal survival, brain derived neurotrophic factor (BDNF)

in two populations; individuals with multiple sclerosis and chronic fatigue syndrome.

BDNF is a protein involved in

the maintenance and maturation of both peripheral and central neurons.

In patients with multiple sclerosis,

BDNF expression is often decreased and

believed to reflect ineffective repair mechanisms.

As a preliminary exploration, we examined

the production of BDNF on the part of peripheral blood mononuclear cells

in three groups:

patients with Chronic Fatigue Syndrome (CFS [n=15]),

patients with multiple sclerosis (n=57), and

a set of putatively healthy controls (n=37).

Methods:

Mononuclear cells were extracted from peripheral blood samples and cultured for 48 hours.

Production of BDNF was evaluated from

phyto-haemagglutinin (PHA) and phorbol-12-myristate-13-acetate (PMA) stimulated and

unstimulated cells.

BDNF levels were determined

using a commercially available enzyme linked immune absorbent assay

(sensitivity: 62.5-4,000 pg/mL).

Results:

Both CFS and MS samples displayed nearly identical levels of BDNF,

levels that were 25 percent of that displayed by the healthy control sample.

For unstimulated cells, the BDNF values were

404.71 pg/ml for the CFS sample,

573.33 pg/ml for the MS sample and

1,114.15 pg/ml for the control sample.

For stimulated cells, the BDNF values were

442.55 pg/ml for the CFS sample,

367.33 pg/ml for the stimulated MS sample, and

1,432.24 pg/ml for the stimulated control sample.

Conclusion:

The deceased production of BDNF on the part of MS patients is consistent with the literature.

However, the decreased production in those with CFS was unexpected and a novel finding.

This finding could reflect

a reduced ability to maintain neuronal structure and function in those with CFS.

Future studies are needed to evaluate for neuronal damage in those with CFS.

bron:

http://omicsonline.org/open-access/brain-derived-neurotrophic-factor-is-decreased-in-chronic-fatigue-syndrome-and-multiple-sclerosis-2155-9562-S12-013.pdf

Met dank aan Rob, ME-de-"strijder" voor een goede zaak...